Takeda's dengue vaccine wins EU approval
Japanese company Takeda's dengue vaccine was authorised for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually. The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue.
- Country:
- Japan
Japanese company Takeda's dengue vaccine was authorised for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.
The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue. There are no antivirals or specific treatments for the flu-like viral disease. While the illness is mostly mild, some people can develop life-threatening complications. Between 20,000 to 25,000 people, mostly children, die each year, according to the World Health Organization.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Takeda
- World Health Organization
- Japanese
- European Union